Oral Session 2-9A MM: Global clinical trials

[OS2-9A-2] Long-term safety of daratumumab plus bortezomib and dexamethasone (D-Vd) in RRMM: CASTOR

Andrew Spencer¹, Vania Hungria², Roman Hajek³, Katja Weisel⁴, Francesca Gay⁵, Meral Beksac⁶, Piruntha Thiyagarajah⁷, Himal Amin⁸, Xiang Qin⁹, Jordan M. Schecter⁸, Pieter Sonneveld¹⁰ (1.Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Clayton, Australia, 2.Irmandade Da Santa Casa De Misericordia De Sao Paulo, Sao Paulo, Federative Republic of Brazil, 3.Fakultni nemocnice Ostrava, Ostrava-Poruba-Poruba, Czech Republic, 4.Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II, Tubingen, Federal Republic of Germany, 5.Division of Hematology, University of Torino, A.O.U. San Giovanni Battista, Torino, Italian Republic, 6.Ankara University, Department of Hematology, Ankara, Republic of Turkey, 7.Janssen Research & Development, LLC, High Wycombe, United Kingdom of Great Britain and Northern Ireland, 8.Janssen Research & Development, LLC, Raritan, United States of America, 9.Janssen Research & Development, LLC, Spring House, United States of America, 10.Department of Hematology, Erasmus MC, Rotterdam, Kingdom of the Netherlands)